Complication of Ventilation Therapy Clinical Trial
Official title:
Intraoperative Protective Ventilation and Postoperative Pulmonary Complications
NCT number | NCT02671721 |
Other study ID # | 2015P001613 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 2016 |
Est. completion date | June 2017 |
Verified date | February 2019 |
Source | Massachusetts General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this pilot study is to identify the optimal way to ventilate patients during abdominal surgery in order to reduce the amount of post-operative pulmonary complications in patients at moderate and high-risk for them.
Status | Completed |
Enrollment | 40 |
Est. completion date | June 2017 |
Est. primary completion date | March 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility |
Inclusion Criteria: - Adults ( 18 years) scheduled for elective surgery expected to last 2 h, - elective intraperitoneal abdominal or pelvic surgery including: gastric; biliary; pancreatic; hepatic; major bowel, ovarian, renal tract, bladder, and prostatic; radical hysterectomy; and pelvic exenteration; - at least intermediate risk of PPCs defined by a risk score 26 Exclusion Criteria: - Inability or refusal to provide consent - Refusal of clinicians caring for patient to follow the protocol - Participation in interventional investigation within 30 days of the time of the study - Pregnancy - Emergency surgery - Severe obesity (above Class I, BMI 35) - Significant lung disease: any diagnosed or treated respiratory condition that (a) requires home oxygen therapy or non-invasive ventilation, (b) severely limits exercise tolerance to <4 METs (e.g. patients unable to do light housework, walk flat at 4 miles/h or climb one flight of stairs), or (c) required previous lung surgery80 - Significant heart disease: cardiac conditions that limit exercise tolerance to <4 METs - Renal failure: peritoneal or hemodialysis requirement or preoperative creatinine 2 mg/dL; - Neuromuscular disease that impairs ability to ventilate without assistance - Severe chronic liver disease (Child-Pugh Score of 10 -15) - Sepsis - Malignancy or other irreversible condition for which 6-month mortality is estimated 50% - Bone marrow transplant. |
Country | Name | City | State |
---|---|---|---|
United States | Massachusetts General Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Massachusetts General Hospital | Mayo Clinic, University of Colorado, Denver |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Intraoperative driving pressure | We will assess intraoperative driving pressure to evaluate respiratory mechanics during surgery. | During abdominal surgery | |
Primary | Intraoperative transpulmonary pressure | We will assess intraoperative transpulmonary pressure to evaluate respiratory mechanics during surgery. | During abdominal surgery | |
Primary | Intraoperative respiratory system compliance | We will assess intraoperative respiratory system compliance to evaluate respiratory mechanics during surgery. | During abdominal surgery | |
Primary | Intraoperative positive end-expiratory pressure (PEEP) levels | We will assess intraoperative PEEP values and their variability between patients and during surgery. | During abdominal surgery | |
Secondary | Intraoperative gas exchange | We will assess intraoperative oxygenation and carbon dioxide elimination. | During abdominal surgery | |
Secondary | Plasma levels of biomarkers of lung injury | We will assess plasma concentrations of biomarkers of lung injury before and after surgery, including biomarkers of inflammation (interleukin-6, IL-6, interleukin-8, IL-8), epithelial injury (soluble form of the receptor for advanced glycation end-products, sRAGE, Club Cell protein-16, CC16), endothelial injury (angiopoietin-2, Ang-2), and endothelial-derived coagulation activation (plasminogen activator inhibitor-1, PAI-1). | During abdominal surgery | |
Secondary | Postoperative Pulmonary Complications | We will assess the incidence and absolute number of postoperative pulmonary complications within the first 7 postoperative days. | Within the first 7 postoperative days. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT02327910 -
The Clinical Value of Applying TOF and TcPO2 to Guide Elderly Patients Extubation
|
N/A | |
Completed |
NCT02337673 -
Screening of Postoperative Pulmonary Complications by Electrical Impedance Tomography
|
||
Completed |
NCT01346709 -
Prospective Evaluation of a RIsk Score for Postoperative Pulmonary COmPlications in Europe
|
||
Completed |
NCT02226809 -
Multi-center Study of Residual Neuromuscular Block Incidence in the Post-anesthesia Care Unit
|
N/A | |
Completed |
NCT01914328 -
Postoperative Pulmonary Complications in Major Abdominal Surgery
|
||
Completed |
NCT01562691 -
Effect of Airway Integrated Nasal Packing With Different Material
|
Phase 4 | |
Completed |
NCT02229591 -
Expiratory Flow Limitation and Postoperative Complications
|
N/A | |
Completed |
NCT01441791 -
PROVHILO:Protective Ventilation During General Anesthesia for Open Abdominal Surgery
|
N/A | |
Completed |
NCT04276584 -
Effect of Speaking Aloud After Abdominal Surgery.
|
N/A | |
Completed |
NCT02851238 -
Driving Pressure and Postoperative Pulmonary Complications
|
N/A |